Shares of Pasithea Therapeutics Corp. (KTTA) surged nearly 47% on Thursday, closing at a two-month high, after an external committee approved advancing its cancer drug trial to the next dosing cohort.

Pasithea Therapeutics Corp. has announced the successful enrollment and initial dosing of three subjects in Cohort 6 of its Phase 1 clinical trial for PAS-004, a candidate for treating ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MIAMI, March 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company ...

MIAMI, April 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company ...

MIAMI - Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech firm focused on central nervous system disorders and cancer with a current market capitalization of approximately $3 million ...

Pasithea Therapeutics Corp. announced that its Vice President of Business Development, Mathew Lazarus, will present at the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference ...

Pasithea Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports ...

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine ...

Poster presentation on Monday, June 2, 2025 from 1:30 - 4:30 PM CDT at the ASCO Annual Meeting MIAMI, April 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea” or the ...